CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15,076 enrolled
Drug / intervention
aspirindrug
Likely dose
aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02697916
NCT02697916N/ACompleted
CompareCT.gov

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness

Duke University·interventional·Posted Mar 3, 2016·Updated Jul 1, 2021

In Brief

A clinical study evaluating aspirin for Atherosclerotic Cardiovascular Disease. Completed, enrolled 15,076 participants across 40 sites.

Detailed Summary

ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD). The primary endpoint is a composite of all-cause death, hospitalization for MI, or hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding with an associated blood product transfusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerotic Cardiovascular Disease
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute, Medidata Solutions, Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN), Greater Plains Collaborative Clinical Data Research Network, Mid-South Clinical Data Research Network, Research Action for Health Network (REACHnet), The Patient-Oriented Scalable National Network for Effectiveness Research, PaTH Clinical Data Research Network, New York City Clinical Data Research Network, The Health eHeart Alliance, OneFlorida Clinical Data Research Network, HealthCore-Anthem Research Network, Humana Inc., The Patient-Centered Network of Learning Health Systems

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 3, 2016
Enrollment StartApr 1, 2016
Primary CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.3 years ago

Interventions

aspirindrug

81mg of aspirin daily vs. 325mg of aspirin daily